Slideshow
Author(s):
Highlights include: "Artificial pancreas" improves glucose control; T1DM often misdiagnosed as T2DM; and a genetic connection for “type 1.5 diabetes.”
Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD
Diabetes Dialogue: What to Know About the Eversense 365 CGM, with Brian Hansen
Endocrinology Month in Review: September 2024
Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD
FDA Clears Eversense 365, Marking First 1-Year CGM Option in Diabetes
GLP-1 RA Linked to Lower Risk of Cirrhosis Development in Patients with MASLD